

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE IN RESPECT OF MEDICAL AESTHETIC INDUSTRIAL PARK PROJECT IN CHENGDU

This is a voluntary announcement made by Sinco Pharmaceuticals Holdings Limited (the “**Company**”) with reference made to the announcement of the Company dated 9 September 2021 in connection with the Technological Development Project (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that it has received a letter (the “**Letter**”) from Chengdu Tianfu International Biological City Management Committee* (成都天府國際生物城管理委員會) (the “**Committee**”) on 6 January 2022. In the Letter, the Committee stated that it fully supports the Company’s smart medical aesthetic industrial park project and its research and development and industrialisation of medical aesthetic products such as polycaprolactone, that the Committee will provide a good business environment, quality and efficient government services for the Company’s medical aesthetic industrial park project and the aforesaid research and development and industrialisation of medical aesthetic products, and give support and guarantee in terms of resources and talents. Further, the Committee states that it will assist the Company in building an important research and development sources and industrialisation base in the field of medical aesthetic products, and a special working group has been set up to coordinate matters related to the implementation of the medical aesthetic industrial park project and daily liaison work.

The Company will actively cooperate with the Committee and relevant government authorities in connection with the medical aesthetic industrial park project in Chengdu and negotiate with them for details of government support plans.

The Company will make further announcement(s) to disclose any material updates and progress with respect to the medical aesthetic industrial park project in accordance with Listing Rules and applicable laws and regulations as and when appropriate.

Shareholders and potential investors of the Company should note that this announcement is made on a voluntary disclosure basis to allow the public to understand the Company's latest business development. The medical aesthetic industrial park project may or may not be implemented as described or at all. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 6 January 2022

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.

* *For identification purpose only*